Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study

Background Patient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart® autoinjector facilitates self-administration of subcutaneous interferon β-1a (sc IFN β-1a) and records objective adherence data. The CORE study was under...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	BMC neurology Ročník 17; číslo 1; s. 171 - 5
Hlavní autori:	Zecca, Chiara, Disanto, Giulio, Mühl, Sarah, Gobbi, Claudio
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 04.09.2017 BMC
Predmet:	Adherence Adjuvants, Immunologic - administration & dosage Adult Autoinjector Demyelinating diseases Disabled Persons Female Humans Injections, Subcutaneous Interferon beta-1a - administration & dosage Male Medication Adherence - statistics & numerical data Medicine Medicine & Public Health Middle Aged Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis, Relapsing-Remitting - drug therapy Neurochemistry Neurologists Neurology Neurosurgery Patient Compliance RebiSmart Research Article sc IFN β-1a Self Administration Self Medication - instrumentation Self Report Subcutaneous interferon β-1a Surveys and Questionnaires Adherence Multiple sclerosis Self-reported adherence Subjective adherence RebiSmart Objective adherence sc IFN β-1a Patient adherence Subcutaneous interferon β-1a Autoinjector
ISSN:	1471-2377, 1471-2377
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!